Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer

This study has been completed.
Sponsor:
Information provided by:
University of New Mexico
ClinicalTrials.gov Identifier:
NCT00298064
First received: February 28, 2006
Last updated: January 6, 2010
Last verified: November 2009

February 28, 2006
January 6, 2010
December 2005
February 2008   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00298064 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer
Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer

The Tissue Repository will search for cases, pull slides, Paraffin-embedded tissue (PET) blocks.

This study is done to gather preliminary data for determining the best way to test EGFR expression in patients with cervical cancer who will receive treatment with EGFR inhibitors in the future.

This study is designed to obtain preliminary data of genomic and phenotypic alterations of the EGFR pathway in high grade cervical intraepithelial lesions (HG-SIL) and invasive cervical cancers (CC) to be used later for therapeutic guidance and to evaluate genomic (over-expression, amplification, point mutations, etc.) and phenotypic alterations of other transduction pathways interacting with the EGFR pathway.

Interventional
Not Provided
Not Provided
  • Cervical Cancer
  • Cervix
Genetic: Tissue Repository
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
February 2008
February 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Samples from patients diagnosed with HG-SIL (n=300) and CC (n=300) with a follow-up of at least 24 months, existing at the Department of Pathology will be retrieved by the Tissue Repository, de-identified them and provided with code numbers that will not be linked to patient's data.

Exclusion Criteria:

  • None Specified.
Female
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00298064
INST 0548C
Yes
Claire Verschraegen, MD; Principal Investigator, University of New Mexico
University of New Mexico
Not Provided
Principal Investigator: Claire Verschraegen, MD University of New Mexico
University of New Mexico
November 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP